Congress Materials – International Myeloma Society (IMS 2025)
2025 International Myeloma Society | Sep 17-20 | Toronto, Canada
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel
Yi Lin, Rocio Montes de Oca, Binod Dhakal, Roberto Mina, Salomon Manier, Paula Rodríguez-Otero, Yaël Cohen, Dominik Dytfeld, Feng Wang, Katharine Henry, Ana Caroline Sa Costa, Tzu-Min Yeh, Ana Slaughter, Nikoletta Lendvai, Indrajeet Singh, Jieqing Zhu, Da Xu, Mythili Koneru, Nitin Patel, Vicki Plaks, Adam Cohen
This document will be available on September 17 2025
Analysis of Patients With Prior BCMA-Targeted Therapy and Those Achieving CR in REALiTAL: A Multi-Country Observational Study of Talquetamab in RRMM Outside of Clinical Trials
K. Martin Kortüm, Hila Magen, Vitaliy Mykytiv, Carmine Liberatore, Elena Zamagni, Matteo Claudio Da Vià, Elisabetta Antonioli, Markus Hansson, Diptendu Santra, Danielle Greer, Krystof Subrt, Peter Hu, Eric Aeby, Nicholas Francella, Natalia Martin Suñe, Rakesh Popat, Aurore Perrot, Katarina Uttervall
This document will be available on September 18 2025
Clinical Features and Management of GPRC5D Related AE in Chinese Relapsed/Refractory Multiple Myeloma Patients Treated With Talquetamab: MonumenTAL-1 China Cohort Experience
Gang An, Jie Jin, Zhen Cai, Hongmei Jing, Chengcheng Fu, Pengcheng He, Zhongjun Xia, Qianqian Xu, Rui Liu, Liang Li, Xue Gai, Hong Zhang, Dian Zhu, Xinchao Luo, Michela Campagna, Tara J. Masterson, Bonnie W. Lau, Thomas Renaud, Christoph Heuck, Lugui Qiu
This document will be available on September 18 2025
Comparative Effectiveness of Teclistamab vs Real-World Physician’s Choice of Carfilzomib-and/or Pomalidomide-based Regimens in LocoMMotion and MoMMent in TCE RRMM
María-Victoria Mateos, Katja Weisel, Francesca Ghilotti, Joris Diels, Tassia Decimoni, Pamela Villanova, Anielle Jacomini, Simone Forny, Monserrat Rojas, Mary Slavcev, Marguerite O’Hara, Philippe Moreau
This document will be available on September 17 2025
Cost per Responder Model of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma
Santosh Gautam, Laura Morrison, Philippe Thompson-Leduc, Bronwyn Moore, Avani Samandur, Brian Macomson, Vipin Khare, Xin Yin, Rohan Medhekar
This document will be available on September 17 2025
Dynamic Frailty Analysis of Transplant-Ineligible (TIE) Patients With NDMM in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab (Dara) + Lenalidomide-Dexamethasone (Rd) and Bortezomib-Rd (VRd)
Hira Mian, Thierry Facon, Gordon Cook, Philippe Moreau, Saad Usmani, Shaji Kumar, Salomon Manier, Vania Hungria, Nizar Bahlis, Huiling Pei, Melissa Rowe, Robin Carson, Fredrik Borgsten, Sonja Zweegman
This document will be available on September 17 2025
Economic Value of Tocilizumab Prophylaxis to Prevent Cytokine Release Syndrome During Outpatient Teclistamab or Talquetamab Initiation for Relapsed/Refractory Multiple Myeloma
Amir Ali, Arveen Kaur, Felice Yang, Yi-Hsuan Liu, Joseph Goble, Xinke Zhang, Niodita Gupta-Werner, Tonya Le Blanc, Saurabh Patel, Arielle Bensimon, Ariel Grajales-Cruz
This document will be available on September 17 2025
Effectiveness of Daratumumab plus Bortezomib, Lenalidomide, and Dexamethasone Versus VRd as Frontline Treatment for Transplant Eligible Newly Diagnosed Multiple Myeloma: A Chart Review Study
Carlyn Rose Tan, Lucio Gordan, Joshua Richter, Rachel DiLeo, Prerna Mewawalla, Sarah Larson, Faith Davies, David Oveisi, Niodita Gupta-Werner, Rohan Medhekar, Xin Yin, Annelore Cortoos, Marjohn Armoon, Philippe Thompson-Leduc, Alvi Rahman, Anabelle Tardif-Samson, Claire Vanden Eynde, John Reitan, Gary Milkovich, Joseph Bubalo, Adam Forman, Baylee Bryan, Douglas Sborov, Shuchita Kaila, Saad Usmani
This document will be available on September 18 2025
Effectiveness, safety and clinical use of teclistamab in patients with triple-class-exposed multiple myeloma. Data from the Danish ABC-study.
Astrid Hundebøll Torpe, Jonathan Thorsen, Katrine Fladeland Iversen, Sarah Farmer, Thomas Lund, Charlotte Toftmann Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Dahlager Jørgensen, Maja Ølholm Vase, Manuela Teodorescu, Morten Salomo, Christina Wennerstöm, Agoston Szabo
This document will be available on September 19 2025
Efficacy of Daratumumab-Bortezomib-Lenalidomide-Dexamethasone vs Daratumumab-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar Bahlis, Christopher P. Venner, Marc Braunstein, Jianming He, Sandhya Nair, Andras Borsi, Eric M. Ammann, Melissa Rowe, Robin Carson, Sonja Zweegman
This document will be available on September 17 2025
Efficacy/Safety of Cilta-Cel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline ASCT: Updated Follow-Up From CARTITUDE-2 Cohort D
Yaël C. Cohen, Tessa Kerre, Michel Delforge, María-Victoria Mateos, Jesús San-Miguel, Mounzer Agha, Shambavi Richard, Melissa Alsina, Mohamed Amine Bayar, Bheemshankar Chelluri, Katherine Li, Lee Jablow, Helen Varsos, Christina Corsale, Ioanna Tsakos, Kevin De Braganca, Ana Caroline Costa Sa, Tamar Lengil, Nikoletta Lendvai, Nitin Patel, Christopher del Corral, Mythili Koneru, Bertrand Arnulf, Wilfried Roeloffzen
This document will be available on September 19 2025
eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma
Rafael Fonseca, Sibel Blau, Cindy Varga, Baylee Bryan, Jack Khouri, Lisa Raff, David Oveisi, Jennifer M. Ahlstrom, Amir Ali, Muhamed Baljevic, Binod Dhakal, Alexander Glick, Natalia Neparidze, Matthew J. Pianko, Joshua Richter, Carlyn Rose Tan, Eric Wu, Fan Mu, Yan Wang, Santosh Gautam, Rohan Medhekar, Xinke Zhang, Zaina Qureshi, Agne Paner-Straseviciute, Shuchita Kaila
This document will be available on September 17 2025
Long-Term Follow-Up From MajesTEC-1 China Cohort of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Efficacy Updates, Infection Profile and Immunoglobulin Usage
Zhen Cai, Zhongjun Xia, Ai-Li He, Yujun Dong, Yafei Wang, Aijun Liao, Yang Song, Juanjuan Song, Rui Liu, Hongye Chen, Athena Zuppa, Katherine Chastain, Latisha Watkins, Xinchao Luo, Lin Huang, Bing Ning, Wannan Chen, Angeline Zhu, Xiaohong Wang, Weijun Fu, Ting Niu, Juan Du
This document will be available on September 18 2025
Outcomes of outpatient step-up dosing (SUD) of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma (RRMM): findings from a large network of community practices in the USA
Lisa Raff, Joseph Abrams, Cathryn Barisonek, Kimberly Melgarejo, Maithili Deshpande, Felice Yang, Niodita Gupta-Werner, Xinke Zhang, Tonya Le Blanc, Saurabh Patel, Vanessa Mirsky
This document will be available on September 19 2025
Outcomes of Teclistamab (Tec) step-up dosing in outpatient/ hybrid settings among a large sample of relapsed refractory multiple myeloma (RRMM) patients treated with Tec
Binod Dhakal, Gilbert Ko, Jinghua He, Wenze Tang, Sarah Lucht, Camryn Craig, Bruce Feinberg, Tonya LeBlanc, Niodita Gupta-Werner, Shuchita Kaila, Peter Voorhees
This document will be available on September 19 2025
Patient-Reported Outcomes (PROs) and Safety in Patients (Pts) With NDMM Achieving MRD Negativity and ≥CR (MRDneg) in the Phase 3 PERSEUS and CEPHEUS Trials
Jesús San-Miguel, Saad Usmani, Sonja Zweegman, Philippe Moreau, Mario Boccadoro, Meletios Dimopoulos, Hermann Einsele, Paula Rodríguez-Otero, Thierry Facon, J. Blake Bartlett, Thomas Prior, Katharine Gries, Yan Wang, Huiling Pei, Maria Krevvata, Diego Vieyra, Anna Sitthi-Aamorn, Melissa Rowe, Robin Carson, Nikhil Munshi, Bruno Paiva, Pieter Sonneveld
This document will be available on September 18 2025
Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: RedirecTT-1
Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V Matous, Laura Rosiñol, Koichi Onodera, Surabhi Bajpai, Vikram Kurra, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiashen Lu, Nicholas Au, Maria Krevvata, Ashwini Kumar, Saad Z Usmani, Yaël C Cohen
This document will be available on September 17 2025
Post-Induction Outcomes and Updated Minimal Residual Disease Analysis From GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
Marc Raab, Niels Weinhold, K. Martin Kortüm, Jan Krönke, Lilli Podola, Uta Bertsch, Julia Mersi, Stefanie Huhn, Michael Hundemer, Roland Fenk, Katja Weisel, Alexander Brobeil, Elias Mai, Natalie Schub, Florian Bassermann, Monika Engelhardt, Mathias Hänel, Hans Salwender, Raphael Teipel, Mohamed Amine Bayar, Elena Ershova, Bas Koster, Hartmut Goldschmidt, Hermann Einsele, Leo Rasche
This document will be available on September 17 2025
Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies With T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients
Raj Kurupati, Douglas Marvel, Gourav Choudhary, Joseph Portale, Mahipal Suraneni, Deeksha Vishwamitra, Jason Brayer, Nicholas Hein, Xuechen Wang, Nikoletta Lendvai, Jordan Schecter, J. Blake Bartlett, Vicki Plaks
This document will be available on September 17 2025
Quality-Adjusted Survival Analysis of Cilta-Cel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma Patients Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population
Surbhi Sidana, Leyla Shune, Luciano Costa, Roberto Mina, Rafal Slowik, Jianming He, João Mendes, Jackie Kwong, Seina Lee, Rakesh Popat, Cyrille Touzeau
This document will be available on September 19 2025
Real-World Burden of Infection Among Triple-Class–Exposed Patients With Relapsed/Refractory Multiple Myeloma
Samer Al Hadidi, Eric Chinaeke, Hoa Le, Jinghua He, Helen Pai, Saurabh Patel, Agne Paner-Straseviciute, Jessica Fowler, Tonya Le Blanc, Niodita Gupta-Werner, Xinke Zhang
This document will be available on September 18 2025
Real-world characteristics and outcomes of patients with relapsed or refractory multiple myeloma treated with talquetamab: Early results from eMMpower consortium
Jack Khouri, Rafael Fonseca, Cindy Varga, Sibel Blau, Lisa Raff, Baylee Bryan, Eric Chinaeke, Yi-hsuan Liu, Santosh Guatam, Yan Wang, Marie Louise Edwards, Ryan Simpson, Saurabh Patel, Agne Paner-Straseviciute, Xinke Zhang, Douglas Sborov
This document will be available on September 17 2025
Real-World Healthcare Resource Utilitzation (HCRU) Following Outpatient (OP) or Inpatient (IP) Administration of Ciltacabtagene Autoleucel (Cilta-Cel)
Murali Janakiram, Lin Fan, Victoria Alegria, Matthew Perciavalle, Bruno Emond, Jessica Maitland, Todd Bixby, Saurabh Nagar, Zaina Qureshi, Dima Danai
This document will be available on September 19 2025
Real-World Healthcare Resource Utilization and Costs Among Triple-Class–Exposed Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease in the United States
Hans Lee, Jennifer Harper, Hoa Le, Elissa Min, Jinghua He, Ruibin Wang, Saurabh Patel, Niodita Gupta-Werner, Xinke Zhang
This document will be available on September 18 2025
Real-World Long-Term Effectiveness and Safety Outcomes Among Patients Receiving Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Carlyn Rose Tan, Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Kylee Maclachlan, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Sridevi Rajeeve, Hamza Hashmi, Gunjan Shah, Michael Scordo, Heather Landau, Sergio Giralt, Alexander Lesokhin, Neha Korde, Francesco Maura, Maximilian Merz, Gilbert Ko, Niodita Gupta-Werner, Jessica Fowler, Saad Usmani
This document will be available on September 19 2025
Real-World Outcomes Among Patients with Relapsed or Refractory Multiple Myeloma Initiating Teclistamab at a Large Community Oncology Center in the US
Yair Levy, Laura Ensley, Siraje Mahmud, Monica Lisi, Arveen Kaur, Gilbert Ko, Felice Yang, Niodita Gupta-Werner, Jessica Fowler, Lorraine Brisbin, Steven Paulson
This document will be available on September 17 2025
Real-world safety outcomes and healthcare resource utilization (HCRU) during outpatient, inpatient, and hybrid step-up dosing (SUD) of teclistamab (Tec) and talquetamab (Tal): a chart review study
Cindy Varga, Jack Khouri, David Oveisi, Sibel Blau, Baylee Bryan, Gilbert Ko, Santosh Gautam, Niodita Gupta-Werner, Xinke Zhang, Fan Mu, Ryan Simpson, Joshua Young, Tonya LeBlanc, Saurabh Patel, Shuchita Kaila, Douglas Sborov, Lisa Raff
This document will be available on September 19 2025
Real-World Treatment Patterns, Effectiveness, and Safety of Daratumumab-based Regimens in Chinese Patients With Multiple Myeloma: Final Analysis of the MMY4032 Study
Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu
This document will be available on September 19 2025
Recent Trends in Real-World Frontline Treatment Patterns and Outcomes for Patients with Multiple Myeloma in the United States
Joshua Richter, Santosh Gautam, Xin Yin, Philippe Thompson-Leduc, Alvi Rahman, Anabelle Tardif-Samson, Elizabeth Hore, Patrick Lefebvre, Marjohn Armoon, Phyu Thin Naing, Rohan Medhekar
This document will be available on September 19 2025
Reshaping Treatments: Insights From the BiTAL Study on Talquetamab in Relapsed Refractory Multiple Myeloma
Paula Rodriguez-Otero, Marcos Lorenzo Pérez, Ana Saus Carreres, Elena Fernández Poveda, Ana Pilar González Rodríguez, Sunil Lakhwani Lakhwani, Juan Luis Reguera Ortega, José María Sánchez Pina, Ana Sánchez Quintana, Miriam González Pardo, Maria-Jesus Blanchard Rodriguez, María Victoria Mateos Manteca
This document will be available on September 19 2025
Subcutaneous Daratumumab + Bortezomib, Cyclophosphamide, and Dexamethasone in Asian Patients With Newly Diagnosed Light-Chain (AL) Amyloidosis: Subgroup Final Analysis of the Phase 3 ANDROMEDA Study
Kenshi Suzuki, Kihyun Kim, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, Chang-Ki Min, Fude Zhou, Shinsuke Iida, Nagaaki Katoh, Tomoaki Fujisaki, Ho-Jin Shin, Efstathios Kastritis, Jin Lu
This document will be available on September 17 2025
Talquetamab Dosing Strategies in the United States: Real-World Insights From Over 250 Patients
Rahul Banerjee, Ruibin Wang, Yi-Hsuan Liu, Jinghua He, Saurabh Patel, Xinke Zhang
This document will be available on September 19 2025
Treatment Patterns and Outcomes in the Second and Third Lines and After Triple-Class Exposure: Subanalysis of the Latin American Multiple Myeloma Registry Study (MYLACRE)
Vania Hungria, Kenny Galvez, Guillermina Remaggi, Natalia Schutz, Rosane Bittencourt, Angelo Maiolino, Guillermo Quintero, María Cugliari, Walter Tobias, Carolina Villarim, Edvan Crusoe, Alicia Enrico, Mariana Fernandez, Monserrat Rojas, Pamella Villanova, Damila Trufelli, Rafael Gaiolla
This document will be available on September 17 2025
Trial in Progress: REALiTEC-2, an International Retrospective Study of Clinical Outcomes in Patients With Relapsed Refractory Multiple Myeloma Treated With Teclistamab in the Real World
Aurore Perrot, K. Martin Kortüm, Katarina Uttervall, Pavel Smirnov, Peter Hu, Diptendu Santra, Claire Albrecht, Eva Rubio-Azpeitia, Rakesh Popat
This document will be available on September 18 2025
Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Jing Christine Ye, Noa Biran, Sandhya Nair, Xiwu Lin, Keqin Qi, Eric M. Ammann, Thomas Renaud, Bonnie W. Lau, Jenny Zhang, Trilok Parekh, Kathleen Gray, Xinke Zhang, Luciano Costa
This document will be available on September 19 2025
Updated Efficacy and Safety Results of Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: AURIGA Study
Larry Anderson , Alfred Chung, Laahn Foster, Chakra Chaulagain, Erin Pettijohn, Andrew Cowan, Caitlin Costello, Sarah Larson, Douglas Sborov, Kenneth Shain, Rebecca Silbermann, Peter Voorhees, Robert Rifkin, Maria Krevvata, Mai Ngo, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S Lin, Ashraf Badros
This document will be available on September 20 2025
Value of the Treatment-Free Period Following Ciltacabtagene Autoleucel Infusion in Patients With Relapsed/Refractory Multiple Myeloma: Findings From a Qualitative Interview Study
Rebecca Crawford, Beth Gibson, Lynda Doward, Alexis Oldfield, Andre De Champlain, João Mendes, Seina Lee
This document will be available on September 17 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
